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Clinicopathologic Significance of Inflammasome Activation 
in Autoimmune Diseases
J. Michelle Kahlenberg1  and Insoo Kang2
Autoimmune diseases are characterized by dysregulated immune tolerance to self and inflammatory damage 
to tissues and organs. The development of inflammation involves multiple innate and adaptive immune pathways. 
Inflammasomes are multimeric cytosolic protein complexes that form to mediate host immune responses upon 
 recognizing pathogen- or damage- associated molecular patterns via pattern- recognition receptors (PRRs). The ac-
celerating pace of inflammasome research has demonstrated important roles for inflammasome activation in many 
pathologic conditions, including infectious, metabolic, autoinflammatory, and autoimmune diseases. The inflammas-
ome generally comprises a PRR, procaspase 1, and an adaptor molecule connecting the PRR and procaspase 1. 
Upon inflammasome activation, procaspase 1 becomes active caspase 1 that converts pro–interleukin- 1β (proIL- 1β) 
and proIL- 18 into mature and active IL- 1β and IL- 18, respectively. The cytokines IL- 1β and IL- 18 have multipotent 
effects on immune and nonimmune cells and induce and promote systemic and local inflammatory responses. Hu-
man studies have shown increased levels of these cytokines, altered activation of inflammasome- related molecules, 
and/or the presence of inflammasome activators in rheumatic diseases, including systemic lupus erythematosus, 
rheumatoid arthritis, crystal- induced arthropathies, and Sjögren’s syndrome. Such changes are found in the primary 
target organs, such as the kidneys, joints, and salivary glands, as well as in the cardiovascular system. In animal mod-
els of rheumatic diseases, inflammation and tissue damage improve upon genetic or pharmacologic targeting of the 
inflammasome, supporting its pathogenic role. Herein, we review the clinicopathologic significance and therapeutic 
targeting of inflammasome activation in rheumatic diseases and related conditions based on recent findings.
Introduction
Inflammation plays a critical role in the pathogenesis of 
rheumatic diseases, including systemic lupus erythematosus 
(SLE), rheumatoid arthritis (RA), and crystal- induced arthrop-
athies. Multiple innate and adaptive immune pathways and 
molecules are involved in the development of inflammation. 
Germline- encoded pattern- recognition receptors (PRRs), like 
Toll- like receptors (TLRs), expressed by innate immune cells 
recognize pathogen- associated molecular patterns (PAMPs) 
and damage- associated molecular patterns (DAMPs), which 
are derived from invading pathogens and stressed host cells, 
respectively. Upon recognizing these molecules, the innate 
immune cells produce an array of inflammatory molecules such 
as interleukin- 1β (IL- 1β) and IL- 18, whose maturation and 
secretion are regulated by multiprotein complex inflammas-
omes (1,2). An increasing body of evidence supports the notion 
that the inflammasome plays a role in rheumatic diseases such 
as SLE, crystal- induced arthropathies, and RA. In this review, 
we discuss the biologic processes, clinical significance, and 
therapeutic targeting of inflammasome activation in rheumatic 
diseases and related conditions, focusing on recent advances.
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Inflammasome types and activation
Inflammasomes are multimeric cytosolic protein complexes 
that form to mediate host immune responses upon sensing 
PAMPs or DAMPs (1,2). Assembly of an inflammasome cleaves 
procaspase 1 into active caspase 1 that converts proIL- 1β and 
proIL- 18 into mature and active IL- 1β and IL- 18, respectively. 
Inflammasome activation can lead to pyroptosis, a type of inflam-
matory cell death, and active caspase 1 enables the unconventional 
 secretion of numerous cytosolic proteins (3). The inflammasome 
Figure 1. Structures and triggers of canonical and noncanonical inflammasomes. Canonical inflammasomes that contain caspase 1 can 
be classified into distinct types based on the presence of the sensor proteins NLRP1, NLRP3, NLRC4, AIM2, or pyrin, which recognize 
different triggers. Noncanonical inflammasomes that contain caspase 4 or 5 in humans and caspase 11 in mice can directly interact with 
the lipid A moiety of lipopolysaccharides (LPS). Triggers of individual inflammasomes are shown. FIIND = function to find domain; NBD = 
nucleotide- binding domain; LRR = leucine- rich repeat; PYD = pyrin domain; CARD = caspase activation and recruitment domain; 
p10 = caspase 1 p10; CASP1 = caspase 1; MSU = monosodium urate monohydrate; CPPD = calcium pyrophosphate dihydrate; ROS = 
reactive oxygen species; PAMPs = pathogen- associated molecular patterns; DAMPs = damage- associated molecular patterns; dsDNA = 
double- stranded DNA; snRNP = small nuclear RNP; HIN200 = hematopoietic interferon- inducible nuclear protein 200; BB = bBox zinc- finger 
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typically  comprises 3 components: 1) a PRR sensing PAMPs or 
DAMPs, 2) procaspase 1, and 3) an adaptor molecule like ASC 
that links the sensor and procaspase 1 (1,2). Based on the types 
of PRRs present in individual inflammasomes, they can be classi-
fied into nucleotide- binding oligomerization domain–like receptor 
(NLR), absent in melanoma 2 (AIM2)–like receptor (ALR), and pyrin 
inflammasomes (Figure 1). The NLR inflammasome family mem-
bers, which include NLRP1, NLRP3, and NLRC4, have a central 
nucleotide- binding domain, a C- terminal leucine- rich repeat, and a 
pyrin or caspase activation and recruitment domain (CARD) (1,2). 
PRRs of individual inflammasomes can sense distinct stimuli (Fig-
ure 1). AIM2 recognizes intracytoplasmic DNA, whereas NLRP3 
can be triggered by PAMPs, DAMPs, and even environmental 
chemicals (e.g., silica) (1,2). While caspase 1–containing inflam-
masomes are classified as canonical inflammasomes, noncanon-
ical inflammasomes containing caspase 4 or 5 and caspase 11 
are observed in humans and mice, respectively. The CARD motif 
of caspases 4, 5, and 11 can directly bind with the lipid A moiety 
of intracellular lipopolysaccharide, leading to the activation of these 
caspases and subsequent secretion of IL- 1β and IL- 18 (2,3).
The best- characterized inflammasome is the NLRP3 inflam-
masome (3). While intracellular levels of ASC and procaspase 
1 are stable, the quantity of NLRP3 present in resting myeloid 
cells (e.g., human monocytes) is insufficient to allow activation 
in response to stimuli, suggesting that NLRP3 is a limiting factor 
regulating NLRP3 inflammasome activation (3–5). NLRP3 that is 
up- regulated by PRRs via active NF- κB can be regulated by post-
translational mechanisms including phosphorylation and ubiquit-
ination (3). Reactive oxygen species (ROS), K+ efflux, ATP, and 
lysosomal rupture can mediate the activation of the NLRP3 inflam-
masome (3). High levels of extracellular ATP also result in K+ efflux 
by activating the P2X purinoceptor 7 (P2X7 purinoceptor) channel. 
Many NLRP3 triggers increase mitochondrial ROS production, 
and NLRP3 inflammasome activation is inhibited by preincubation 
with some antioxidants (3). Never in mitosis gene–related protein 
kinase 7 plays an essential role in the formation of the NLRP3 
inflammasome in murine macrophages by directly interacting with 
NLRP3 (6). Bruton’s tyrosine kinase (BTK), which is involved in B 
cell receptor and TLR signaling, physically interacts with ASC and 
NLRP3, and inhibiting BTK suppresses NLRP3 inflammasome 
activation (7). These findings highlight the fundamental role of the 
inflammasome in handling attacks and dangers posed to the host 
through interacting with multiple cellular and molecular pathways.
The inflammasome and rheumatic diseases
Inflammasomes regulate the maturation and secretion of IL- 1β. 
IL- 1β has pleiotropic effects on multiple immune and nonimmune 
cells and is responsible for many clinical manifestations in autoim-
mune and inflammatory diseases (8). As an endogenous pyrogen, 
IL- 1β induces fever, which is frequently seen in rheumatic diseases. 
IL- 1β serves as an upstream regulator of innate and adaptive 
immune responses by promoting the production of other inflamma-
tory cytokines, such as IL- 6, tumor necrosis factor (TNF), and IL- 17 
(8,9). Similarly, IL- 18 is known to enhance  interferon-­γ (IFNγ) pro-
duction by Th1 cytokines. Thus, it is natural to consider the poten-
tial role of the inflammasome in inflammation and tissue damage in 
rheumatic diseases. A body of evidence supporting this notion has 
accumulated over a decade through human and animal studies.
Several molecules known to be causative of or pathogenic 
for rheumatic diseases can activate inflammasomes, leading to 
the production of IL- 1β and IL- 18. These include monosodium 
urate monohydrate and calcium pyrophosphate dihydrate (CPPD) 
crystals, which are responsible for gout and pseudogout, respec-
tively (10), as well as double- stranded DNA (dsDNA) and U1 
small nuclear RNP (U1 snRNP)–containing lupus immune com-
plexes (Figure 2) (11,12). Also, monocytes and macrophages in 
patients with rheumatic diseases, especially SLE, have increased 
expression of inflammasome components and/or enhanced 
inflammasome activation (13,14), suggesting the existence of an 
intrinsic alteration in the intracellular inflammasome pathways. 
Of note, some polymorphisms of inflammasome- related genes 
have been shown to be associated with susceptibility, severity, 
and/or treatment response in rheumatic diseases, including SLE 
and RA (15–20). Improvement in disease activity was observed 
in murine models of SLE, RA, crystal- induced arthropathies, and 
Sjögren’s syndrome (SS) when inflammasome activation was tar-
geted genetically or chemically (see details below). In addition to 
the immune system, dysregulated inflammasome activation in 
rheumatic diseases likely affects multiple organ systems, including 
the kidneys, lungs, eyes, and cardiovascular system, contributing 
to morbidity and mortality (21,22). The links between inflammas-
omes and individual rheumatic diseases are discussed below.
The inflammasome and SLE
Possible dysregulation of inflammasome activation in lupus 
was identified as early as 3 decades ago. Those studies reported 
increased IL1b gene expression and IL- 1β production in the kid-
neys of lupus- prone mice and from human monocytes, respec-
tively (23,24). Although the exact mechanisms for these findings 
were not clear at that time, the discovery of the inflammasome 
and its role in IL- 1β secretion revealed new insights into the patho-
genesis of lupus. Unique to SLE, autoimmune features, such as 
immune complexes, can provoke the inflammatory response. 
Immune complexes containing dsDNA or U1 snRNP can acti-
vate the NLRP3 inflammasome in human monocytes, leading 
to the production of IL- 1β and IL- 18 (11,12). Several pathways, 
including ROS, K+ efflux, and TLRs, are involved in this phenom-
enon, as evidenced by the fact that inhibition of ROS production, 
K+ efflux, and TLR activation suppressed cytokine production. 
IL- 1β released from such activated monocytes enhanced Th17 
responses, which are increased in lupus, supporting the notion that 
inflammasome activation is implicated in  dysregulated  adaptive 
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immune responses in lupus (12). Confirming this chronic inflam-
masome activation, patients with SLE demonstrate increased cir-
culatory levels of IL- 1β and IL- 18 (22,25).
Neutrophil extracellular traps (NETs) that contain self- DNA and 
other molecules such as the antibacterial protein LL- 37 play a role 
in the pathogenesis of lupus. Both NETs and LL- 37 activate the 
inflammasome in human and murine macrophages, leading to the 
release of IL- 1β and IL- 18 (Figure 2) (13). The released IL- 18 stim-
ulates NETosis in human neutrophils, suggesting a feedforward 
inflammatory loop involving NET and inflammasome activation. 
Inflammasome activation and IL- 18 production can be responsible 
in part for vascular dysfunction in SLE through impairment of vas-
cular repair mechanisms; caspase 1 inhibition and IL- 18 neutrali-
zation have been shown to improve dysfunctional SLE endothelial 
progenitor cell differentiation (22). Also, patients with SLE had 
increased AIM2 expression correlating with disease activity, and 
blocking AIM2 expression in lupus- prone mice reduced disease 
activity (26). The association of IL1B, IL18, and NLRP1 polymor-
phisms with SLE has been demonstrated in patients of different 
ethnic backgrounds, supporting the possible genetic implication of 
certain inflammasome- related genes in SLE (15–17).
Monocytes and macrophages from patients with SLE appear 
to be more prone to inflammasome activation (13,14). Patients 
with SLE have enhanced inflammasome activation in monocyte- 
derived macrophages upon NET and LL- 37 stimulation (13). 
Also, freshly isolated monocytes from patients with SLE demon-
strate increased expression of NLRP3, AIM2, and CASP1 (14). 
The expression of these genes is correlated with IFN scores, and 
IFNα enhances caspase 1 expression via IFN regulatory factor 1 
 (Figure 2). These findings support the notion of a positive interac-
tion between type I IFN and the inflammasome in lupus through 
priming of monocytes for robust inflammasome activation. Indeed, 
patients with SLE have increased levels of caspase 1 activation in 
monocytes that correlate with serum levels of IL- 1β, anti- dsDNA 
antibodies, and disease activity (25). Also, ATP- induced IL- 1β pro-
duction has been shown to be increased in the macrophages of 
patients with SLE (27). Recently, the role of macrophage migra-
tion inhibitory factor (MIF) in up- regulating NLRP3 expression was 
demonstrated in human monocytes stimulated with the U1 snRNP 
lupus immune complex (4). Upon exposure to the latter, human 
monocytes produced MIF, and blocking MIF binding to its receptor 
CD74 suppressed NLRP3 expression and subsequent caspase 1 
activation (4). The expression levels of MIF and CD74 correlated at 
the single cell level, supporting the autocrine and paracrine effects 
of MIF in regulating NLRP3. Of note, a separate study showed 
that MIF was implicated in activating the NLRP3 inflammasome 
through its interaction with NLRP3 (5). These findings support 
the notion that MIF plays a role in lupus  pathogenesis, which is 
Figure 2. Schematic representation of the mechanisms of inflammasome activation in rheumatic diseases. Lupus immune complexes of 
double- stranded DNA (dsDNA) and U1 small nuclear RNP (U1 snRNP) affect inflammasome activation via inducing NETosis, macrophage 
migration inhibitory factor (MIF) in monocytes, and interferon- α (IFNα) in plasmacytoid dendritic cells (pDCs). In rheumatoid arthritis (RA), tumor 
necrosis factor (TNF), hypoxia, oxidized low- density lipoprotein (LDL), and high mobility group box chromosomal protein 1 (HMGB- 1) affect 
NLRP3 expression and inflammasome activation. In gout and pseudogout, monosodium urate monohydrate (MSU) and calcium pyrophosphate 
dihydrate (CPPD) crystals activate the NLRP3 inflammasome. Monocytes, macrophages, and podocytes with activated inflammasome produce 
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further  substantiated by human and animal studies showing the 
 relationship of MIF  genotypes to SLE and improvement in murine 
lupus upon blocking MIF, respectively (28,29).
Consistent with the results of human studies, animal studies 
indicate a pathogenic role for inflammasomes in lupus. In one study, 
mice lacking caspase 1 were protected against autoantibody pro-
duction, type I IFN response, and glomerulonephritis upon pristane 
challenge (30). In the same lupus animal model, caspase 1 defi-
ciency reduced vascular dysfunction, which is a major contributor 
to mortality in human lupus (30). Also, Nlrp3- R258W mice carrying 
the gain- of- function mutation exhibited significantly higher mortal-
ity and renal damage upon pristane challenge (31). Lupus- prone 
MRL/lpr mice have been shown to have increased expression of 
P2X7, NLRP3, ASC, active caspase 1, and IL- 1β in the kidneys 
(32). Blockade of P2X7 purinoceptor suppressed lupus nephritis in 
MRL/lpr mice by inhibiting NLRP3 inflammasome activation with 
decreased IL- 1β and IL- 17 levels (32).
A recent study showed no effect of IL- 1β deficiency on lupus 
nephritis in NZM2328 mice injected with the TLR- 7 agonist R848 
(33). Given the role of inflammasomes in regulating multiple immune 
molecules, including IL- 18, it is likely that targeting only IL- 1β may 
not be sufficient to suppress disease activity. The serine/threonine 
kinase glycogen synthase kinase 3β (GSK- 3β) is a positive regulator 
of NF- κB activation. Thiadiazolidinone 8 (TDZD- 8), a selective inhib-
itor of GSK- 3β, inhibited caspase 1 activation and IL- 1β production 
and reduced anti- dsDNA antibody levels and renal disease in a study 
using MRL/lpr and NZB × NZW F1 mice (34). This finding could be 
related to the suppressive effect of TDZD- 8 on NF- κB activation, 
which up- regulates NLRP3 expression (35). A20, encoded by TNF- 
induced protein 3, is a potent negative regulator of inflammation, 
and its gene polymorphisms are associated with autoimmunity, 
including SLE. A20 was found to suppress NF- κB and caspase 1 
activity (36), and its overexpression reduced nephritis in mice with 
pristane- induced lupus by inhibiting NF- κB and NLRP3 (37).
The NLRP3 inflammasome contributes to the development 
of proteinuria in lupus nephritis by affecting podocyte function. 
NLRP3 inflammasome activation was detected in podocytes 
from patients with lupus nephritis and lupus- prone mice, and the 
selective NLRP3 inhibitor MCC950 ameliorated proteinuria and 
renal histologic lesions in lupus- prone mice (21). Pim- 1, a member 
of the Pim family of serine/threonine kinases, promotes NLRP3 
inflammasome activation in human podocytes in response to anti- 
dsDNA antibody–positive serum by increasing the intracellular 
calcium concentration, which regulates NLRP3 inflammasome 
activation (38). In contrast to the results of most studies, a few 
studies have shown decreased levels of inflammasome activation 
or related molecules in lupus. NZB mice that develop autoim-
mune hemolytic anemia express high levels of the AIM2 antag-
onist p202 and an NLRP3 gene mutation, leading to impaired 
IL- 1β  production, while lupus- prone (NZB × NZW)F1 mice have 
been shown to have reduced NLRP3 and AIM2 inflammasome 
responses (39). Also, lupus- like autoimmunity became more 
severe in C57BL/6-lpr/lpr mice deficient in Nlrp3 and Asc (40). 
Another study identified decreased expression of NLRP3 and 
ASC genes in peripheral blood mononuclear cells (PBMCs) from 
lupus patients but increased expression of CASP1, IL1B, and IL18 
in PBMCs (41). Nevertheless, a large set of animal and human 
data clearly support the notion that inflammasomes, especially the 
NLRP3 inflammasome, play a role in the pathogenesis of lupus.
The inflammasome and RA
Joint inflammation is initiated by inflammasome activation, 
as is seen in crystal arthropathies such as gout and CPPD crys-
tal deposition disease. In RA, which is characterized by chronic 
inflammation and synovial activation that results in bony erosions, 
the role of the inflammasome may be of a more indirect nature. 
Interest in inflammasome biology in RA is longstanding, as anak-
inra, a soluble IL- 1 receptor antagonist, was the first biologic agent 
approved for the treatment of RA. The success of anakinra as an 
RA therapy was modest at best (42); thus, the links between the 
inflammasome and RA continue to be a subject of debate and a 
topic for further research.
Genetic evidence provides hints, but no definitive links 
between RA and inflammasome biology. Polymorphisms and 
subsequent overexpression of NLRP1 have been linked to an 
increased risk of RA (18). Minor polymorphisms in both NLRP3 
and CARD- 8 (an inflammasome- regulating protein) have been 
shown to be associated with seropositivity and increased dis-
ease severity (43). Cytokine polymorphisms have not been defin-
itive either. Polymorphisms of IL- 1β may be associated with the 
development of RA in certain ethnic populations (19), and IL- 18 
polymorphisms may also increase the risk of RA (20). Overall, the 
relationship between RA and the inflammasome may reflect the 
inflammatory activity in the joint itself, rather than a true genetic 
etiology of the disease.
Data from human studies support the notion that the 
inflammasome plays a role in RA. Expression of inflammasome- 
associated proteins in the joint is increased but varies with the 
cell population analyzed. Endothelial and inflammatory cells in 
the RA synovium express all components needed for inflammas-
ome activation, but synovial fibroblasts do not express NLRP3 
(44). Importantly, many RA- associated joint changes prime for 
inflammasome activation. TNF up- regulates key components 
of the inflammasome (45), partially through transforming growth 
factor β–activated kinase 1. Hypoxia, a feature of the inflamed 
synovium, induces IL- 1β protein and NLRP3 expression (46). Oxi-
dized low- density lipoprotein, a modified lipid that is increased in 
RA patients, primes for inflammasome activation in macrophages, 
which results in increased IL- 1β release (47). High mobility group 
box chromosomal protein 1, an alarmin that is associated with the 
development of RA, primes for inflammasome activation as well 
(48). All of these features of RA lead to a state where the inflam-
masome is ready for activation (Figure 2).
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Adaptive immune responses in RA are also regulated by the 
inflammasome. T cells from RA patients express elevated levels 
of active caspase 1 (49,50), which can be triggered by oxidized 
and nonoxidized mitochondrial DNA. Intriguingly, this inflammas-
ome activation contributes to Th17 skewing in vitro (50). These 
data suggest that T cell inflammasome activation may also be an 
important target for RA treatment.
The cytokines produced by inflammasome activation contrib-
ute to the inflammatory phenotype in the RA joint. An imbalance 
of IL- 1β versus IL- 1 receptor antagonist production was noted 
nearly 25 years ago in human RA synovial explants (51). IL- 1β 
activates synovial fibroblasts and induces the production of TNF, 
IL- 6, and matrix metalloproteinases (52). IL- 1α, which is active in 
its full- length and 18- kd cleaved (by caspase 1) mature form, also 
has inflammatory effects on the joint. IL- 1α can promote the mat-
uration of cathepsin B and cathepsin S and works in synergy to 
increase chondrocyte cathepsin B activation and secretion (52).
Murine models support the notion that the inflammasome 
plays a role in inflammatory arthritis, but most research has focused 
on infection or gout- related arthritis. In collagen- induced arthritis 
(CIA), a murine model with features of RA, inhibition of NLRP1 
inflammasome activation is protective (53). Inhibition of P2X7 puri-
noceptor is also protective in a rat streptococcal wall model of 
arthritis (54). Genetic data have not supported a role for either 
caspase 1 or NLRP3 in CIA, as absence of either protein was not 
protective; however, a functional ASC molecule was required for 
disease activity (55). Inhibitor data, however, have demonstrated 
a role for NLRP3 in CIA, since inhibition of NLRP3 via MCC950 
is protective in a CIA model (56). Another orally available NLRP3 
inhibitor, OLT1177, suppresses inflammation in zymosan- induced 
arthritis (57). Myeloid- specific deletion of A20/Tnfaip3 causes ero-
sive polyarthritis, similar to RA. In this model, NLRP3, caspase 1, 
and the IL- 1 receptor are also required for full disease expression 
(58). A comparison of the role of the inflammasome in RA and its 
role in SLE is shown in Table 1.
The inflammasome and other rheumatic 
 autoimmune diseases
Sjögren’s syndrome. SS incorporates pathologic and clin-
ical features of both SLE and RA; thus, it is not surprising to note 
that the inflammasome has been implicated in its pathogenesis as 
well. Circulating levels of IL- 1β and IL- 18, as well as inflammasome 
components such as ASC, are elevated in SS patients (especially 
those with severe SS) compared to healthy controls (59,60). In 
addition, increased expression of NLRP3 inflammasome compo-
nents is detectable in SS salivary gland macrophages in situ (59). 
Both AIM2 and NLRP3 inflammasomes may be involved in SS, 
as stimulation with DNA or NLRP3 agonists induces greater IL- 1β 
production in SS monocytes than control monocytes. In a murine 
model of autoimmune exocrinopathy, inhibition of P2X7 purinocep-
tor is protective against induction of salivary gland inflammation 
(61). In addition, ocular dryness (as seen in primary or secondary 
SS) has been documented as a trigger for the NLRP3 inflammas-
ome in murine models (62).
Celiac disease. IL- 18 signaling has been linked to the 
development of celiac disease through genome- wide association 
studies (63), and this link has been validated in both pediatric and 
adult- onset celiac disease (64). There are data to support a role 
for inflammasome activation in both disruption of epithelial barriers 
and in more generalized inflammation in response to gluten. Sim-
ilar to its inflammasome- promoting effects in SLE monocytes and 
endothelial cells (14,22), IFN can stimulate intestinal epithelial cells 
to promote inflammasome activation and disruption of epithelial 
barriers (65). In addition, circulating monocytes from patients with 
celiac disease mount a more robust NLRP3- dependent inflam-
matory response to gluten peptides than monocytes from healthy 
controls (66). Further research is required to determine whether 
the inflammasome is pathogenically activated in patients with 
celiac disease, contributes to disease phenotypes, and should be 
a target for treatment.
The inflammasome and complications of 
 autoimmunity
Other complications of autoimmune disease are also influ-
enced by inflammasome activation. NLRP3 may be involved in 
lung fibrosis, and increased circulating levels of IL- 18 have been 
identified as a potential biomarker for interstitial lung disease in 
RA patients (67). Increased circulating levels of IL- 1β have been 
documented in patients with severe scleritis (68), and importantly, 
a recent small pilot trial has shown efficacy for anakinra in the 
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treatment of refractory scleritis associated with systemic inflam-
matory disorders (69). Many autoimmune diseases also lead to 
an increased risk of cardiovascular disease, and the inflammas-
ome contributes to this risk through its known effects on plaque 
progression, destabilization of plaque (for review, see ref. 70), and 
promotion of endothelial dysfunction.
Therapeutic targeting of the inflammasome
Interest in inflammasome inhibition is high for many diseases. 
This has been most pronounced for the plethora of autoinflam-
matory syndromes linked to genetic causes of aberrant inflam-
masome activation. Pharmaceutical advances in cytokine and 
inflammasome inhibitors are beneficial for patients with autoim-
mune diseases, and they provide tools, as the science evolves, 
to link inflammasome activity to autoimmunity. Therapies can be 
classified into two categories: cytokine inhibition to block the end 
result of inflammasome activity, or inhibition of the inflammasome 
itself, which may be important for cytokine- and noncytokine- 
related functions of the inflammasome that contribute to disease.
Cytokine inhibition. IL- 1 antagonism has been a long-
standing biologic approach to the management of inflammatory 
diseases (for comprehensive review of drugs, see ref. 71) (Table 2). 
New developments in cytokine blockade include several drugs. 
Lutikizumab, which is a dual IL- 1α and IL- 1β antibody, is being 
evaluated in several diseases including erosive hand osteoarthritis 
(OA) (72) and knee OA (73). While trial results do not support use 
of IL- 1 blockade in OA, the drug may have other indications. Ber-
mekimab is a new human IL- 1α antibody that is in trials for cancer 
therapy (74). IL- 18 inhibition is available via the drug tadekinig alfa, 
which is a recombinant human IL- 18 binding protein that can bind 
IL- 18 and inhibit its function. Tadekinig alfa is not approved by 
the Food and Drug Administration, but it has orphan designation 
for the treatment of hemophagocytic lymphohistiocytosis as well 
as Breakthrough Therapy designation for NLRC4 macrophage 
activation syndrome and X- linked inhibitor of apoptosis protein 
deficiency (71). In addition, tadekinig alfa is being studied in adult- 
onset Still’s disease (75).
Inflammasome inhibition. As research has progressed, 
inflammasome inhibition has been identified as a mechanism for 
several commonly used medications in the treatment of rheu-
matic diseases. Colchicine interrupts inflammasome activation by 
interfering with microtubule assembly (76). Hydroxychloroquine 
interferes with immune complex–triggered activation of the inflam-
masome in monocytes (11,12). Omega- 3 fatty acids, which have 
been shown to be beneficial in RA (77) and possibly lupus (78), 
inhibit inflammasome activation through numerous mechanisms 
(79,80). Thalidomide, which has off- label therapeutic benefit in 
cutaneous lupus (81), inhibits inflammasome activation via repres-
sion of caspase 1 (82). Even nonsteroidal antiinflammatory drugs 
have been shown to have caspase- inhibiting properties. Caspase 
4, but not caspase 1, is inhibited by ketorolac and ibuprofen (83). 
Whether inflammasome inhibition has direct links to the efficacy 
of these drugs in the autoimmune diseases they are used to treat 
remains to be determined.
Direct inhibitors of inflammasome activation are also being 
developed. MCC950, a specific inhibitor of the NLRP3 inflam-
masome (although the exact target has not been localized), 
inhibits inflammasome activation and protects against a myriad 
of inflammatory and autoimmune diseases in many murine mod-
els, including murine lupus nephritis (21) and CIA (56). CY- 09 is 
another small molecule that binds to the ATP- binding motif of 
NLRP3 and can block inflammasome activation in murine mod-
els of type 2 diabetes mellitus and cryopyrin- associated periodic 
Table 2. Strategies for targeting the inflammasome*
Drug Mechanism Target Disease
Cytokine neutralization
Anakinra Soluble IL- 1Ra IL- 1α and IL- 1β RA, CAPS, gout†
Canakinumab Neutralizing IL- 1β antibody IL- 1β CAPS, colchicine- resistant FMF, 
MKD, TRAPS, systemic JIA
Rilonacept Soluble IL- 1R1/IL- 1RAcP IL- 1α and IL- 1β CAPS
Lutikizumab Dual IL- 1α and IL- 1β antibody IL- 1α and IL- 1β Not yet FDA approved
Bermekimab IL- 1α antibody IL- 1α Not FDA approved
Tadekinig alfa Soluble IL- 18 binding protein IL- 18 HLH,† MAS,† XIAP deficiency†
Inflammasome inhibition
Colchicine Interferes with microtubule assembly NLRP3 Gout
Thalidomide Inhibits caspase 1 Caspase 1 CLE
CY- 09 Binds ATP- binding motif NLRP3 Not FDA approved
MCC950 Mechanism unclear NLRP3 Not FDA approved
β-­sulfonyl­nitrile Inhibits inflammasome assembly NLRP3 Not FDA approved
* IL- 1Ra = interleukin- 1 receptor antagonist; RA = rheumatoid arthritis; CAPS = cryopyrin- associated periodic syndromes; FMF = 
familial Mediterranean fever; MKD = mevalonate kinase deficiency; TRAPS = tumor necrosis factor receptor–associated period-
ic syndrome; JIA = juvenile idiopathic arthritis; IL- 1RAcP = IL- 1R accessory protein; HLH = hemophagocytic lymphohistiocytosis; 
MAS = macrophage activation syndrome; XIAP = X- linked inhibitor of apoptosis protein; CLE = cutaneous lupus erythematosus; 
† Not approved by the Food and Drug Administration (FDA) for this indication. 
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syndromes (84). OLT1177, a β- sulfonyl nitrile compound, inhibits 
assembly of the NLRP3 inflammasome and has been shown to 
exert beneficial effects on zymosan- induced murine arthritis (57). 
Small molecule inhibitors of other inflammasomes have not yet 
been identified. Human trials of MCC950 or CY- 09 have not been 
developed as of yet. Other methods of blocking inflammasome 
activation, including inhibiting upstream activators such as NF- κB 
or increasing negative regulators such as Hsp70 (85), also work in 
murine models, but human trials are still pending.
Conclusions
The accelerating pace of inflammasome research has 
demonstrated important roles for inflammasome activation in 
many diseases, both autoinflammatory and autoimmune (Fig-
ure 2). While single cytokine inhibition of IL- 1β may not be over-
whelmingly effective in autoimmune syndromes, further studies 
into the role of IL- 18 blockade and general inflammasome inhibi-
tion may identify effective treatment strategies for diseases such 
as RA or SLE or may offer insight into mechanisms by which 
resulting complications of autoimmunity can be averted. Further 
research will continue to shed light on this ubiquitous inflammatory 
pathway in diseases of the immune system.
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